X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EVX-01 is a peptide-based personalized cancer vaccine which is being evaluated for first-line treatment of metastatic and unresectable cancer. It will engage each patient's immune system to fight off cancer by mounting a targeted response against tumors.
Lead Product(s): EVX-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective & it is being evaluated for the treatment of S. aureus disease.
Lead Product(s): EVX-B1
Therapeutic Area: Infections and Infectious Diseases Product Name: EVX-B1
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
The net proceeds will be used to advance the Company’s preclinical and clinical pipeline, including EVX-01, a personalized cancer immunotherapy intended for the first-line treatment of metastatic and unresectable cancer patients.
Lead Product(s): EVX-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2024
Details:
The net proceeds will be used to advance the Company’s preclinical and clinical pipeline, including EVX-01, a personalized cancer immunotherapy intended for the first-line treatment of metastatic and unresectable cancer patients.
Lead Product(s): EVX-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
Evaxion Biotech is developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs) to provide treatment solutions to cancer patients who are usually unresponsive to cancer immunotherapy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
EVX-01 is a peptide-based personalized cancer vaccine which is being evaluated for first-line treatment of metastatic and unresectable cancer. It will engage each patient's immune system to fight off cancer by mounting a targeted response against tumors.
Lead Product(s): EVX-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
The collaboration aims at developing a novel, prophylactic, mRNA vaccine, EVX-B2, based on Evaxion’s EDEN™ platform, a proprietary AI platform capable of rapidly identifying those antigens that will trigger a highly protective immune response, to discover gonorrhea targets.
Lead Product(s): EVX-B2
Therapeutic Area: Infections and Infectious Diseases Product Name: EVX-B2
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Afrigen Biologics and Vaccines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2023
Details:
EVX-B3, an AI-designed vaccine using both its EDEN™ and RAVEN™ AI platforms to identify protective antigens capable of eliciting both a humoral (antibody) and cellular response to the pathogen.
Lead Product(s): EVX-B3
Therapeutic Area: Infections and Infectious Diseases Product Name: EVX-B3
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
The net proceeds will enable Evaxion to advance its ongoing clinical phase 2 trial, EVX-01, in patients with metastatic melanoma and its next-generation cancer vaccine, EVX-03, towards a Phase 1 clinical trial in patients with lung cancer and other solid tumors.
Lead Product(s): EVX-01,Pembrolizumab
Therapeutic Area: Oncology Product Name: EVX-01
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Negma Group
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 01, 2023
Details:
EVX-B1, a vaccine against Staphylococcus aureus (S. aureus) containing AI-identified antigens, is highly protective against S. aureus disease in preclinical animal models.
Lead Product(s): EVX-B1
Therapeutic Area: Infections and Infectious Diseases Product Name: EVX-B1
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
